Mesoblast Limited vs Old Dominion Freight Line Inc — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Old Dominion Freight Line Inc trades at $181.97 (market cap $37.68B). The key difference: Old Dominion Freight Line Inc is far larger — about 21.5× Mesoblast Limited's market cap, and Old Dominion Freight Line Inc pays a 0.64% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Old Dominion Freight Line Inc for 76 Days on average.
| MESO | ODFL | |
|---|---|---|
Market Cap | $1.75B | $37.68B |
Volume | 239,027 | 1,550,104 |
Sector | Health | Industrials |
52-Week High | $20.96 | $248.73 |
52-Week Low | $13.19 | $126.29 |
Typical Hold Time | 15 Days | 76 Days |
Enterprise Value | $1.83B | $37.42B |
Dividend Yield | — | 0.64% |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Old Dominion Freight Line (ODFL) trades at $181.65, up 3.44% today, showing strong momentum after recent earnings beats. The stock faces technical resistance near $183 while maintaining solid fundamentals with 19.44% net margins and consistent profitability. Recent news highlights a 4.9% rate increase effective October 5, 2026, aimed at offsetting operating costs and supporting service investments. Analyst consensus remains mixed with 36% buy ratings but a $230.93 price target suggesting 27% upside potential from current levels.
ODFL presents a compelling growth story with strong operational metrics and pricing power, though elevated valuation multiples (P/E 34.95) warrant caution. The company's pristine balance sheet with minimal debt and consistent cash flow generation supports long-term stability. Key risks include freight demand volatility and competitive pressures in the trucking industry. Institutional accumulation and recent technical oversold conditions suggest potential for trend reversal despite near-term bearish signals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →